Celgene Corp.

NAS : CELG
Pharmaceuticals
Summit NJ
Revenue (US$ Millions)$7,670
Revenue Growth (%)18.12%
Net Income (Millions)$2,000
Common Shares Outstanding (Millions)$800
Earnings per Share$2.39
Price To Earnings Ratio69.45
Total Equity (Millions)$6,525
Profit Margin 126.07%
Return on Equity35.78%
Long Term Debt (US$ Millions)$6,266
Debt To Equity Ratio (%)0.96%
Market Capitalization (US$ Millions)$89,510
Total Assets (US$ Millions)$17,340
Return on Assets (%)14.95
Current Assets (US$ Millions)$9,713
Inventories (US$ Millions)$393
Current Liabilities (US$ Millions)$2,112
Cost of Goods Sold (US$ Millions)$386
Asset Turnover0.44
Inventory Turnover1.05